Does mTORC1-selective dosing extend lifespan, and is rapamycin's glucose intolerance a cost at all?

Contradiction / tension · confidence 85% · evidence stands at: Clinical outcome in humans (oncology); no ageing endpoint · Atlas ID H2

The gap

The lifespan benefit of blocking mTOR is closely tied to mTORC1, while the main side effect (insulin resistance) comes largely from also disrupting mTORC2. That split is well supported, but it is not the whole story - a feedback loop through S6K1 also contributes to the blood-sugar problem, and nobody has worked out how much each one matters in people. In mice, giving rapamycin less often (weekly instead of daily) avoided the glucose problems while keeping the mTORC1 effect, with no mTORC2 effect detectable - which is not quite the same as saying mTORC2 was untouched. Newer drugs aimed only at mTORC1 showed a low rate of blood-sugar side effects in an early human cancer trial: encouraging, but that trial had no comparison group and was not about ageing.

Technical framing: The lifespan benefit of rapamycin is strongly linked to mTORC1 inhibition, whereas chronic disruption of mTORC2 is a major mechanism behind the insulin resistance (LAM2012). The separation is well supported but NOT exhaustive: this Atlas's own S6K1-IRS1 edge records that the contribution of the S6K1->IRS-1 feedback arm to rapalog dysglycaemia in humans has never been apportioned against mTORC2 loss, so 'all benefit = mTORC1, all harm = mTORC2' overstates what has been shown. QUANTIFIED (full text): ARR2015 - daily 2 mg/kg rapamycin impaired glucose tolerance (+71% AUC) and inhibited BOTH mTORC1 and mTORC2 (AKT-S473), while weekly / every-5-days dosing caused NO glucose impairment and preserved mTORC1 inhibition with no detectable mTORC2 effect -> intermittent dosing decouples benefit from harm in vivo. Wording matters here: 'no detectable mTORC2 inhibition under this assay' is not the same claim as 'mTORC2 was not inhibited'. Dose-response MIL2014 (4.7/14/42 ppm; top dose +23% M / +26% F). PEARL tested 5 vs 10 mg/week but its primary endpoint was visceral fat (missed) - no mTORC1-selective human aging readout exists. Early clinical evidence now exists outside the rapamycin/rapalog class. Bi-steric mTORC1-selective inhibitors (>25-fold selectivity over mTORC2) were validated preclinically (MEN2023: RMC-6272 overcomes drug resistance via complete mTORC1 suppression, sparing mTORC2) and clinically (SCH2025: RMC-5552 Phase 1, n=57 solid tumors) -- treatment-related hyperglycemia was only 4%, which is consistent with the hypothesis that sparing mTORC2 reduces the glucose-intolerance signature seen with chronic rapamycin/rapalogs. Because SCH2025 was open-label, single-arm and had no rapamycin or ATP-site comparator, the low hyperglycaemia rate is a supportive signal, not a causal attribution: it is compared against historical rapalog experience, not against a randomised control. This is the strongest human evidence yet for the mechanistic premise of H2, but it is preliminary, and it comes from an oncology trial, not an aging/longevity endpoint -- the missing link is still a healthspan/lifespan readout for a selective inhibitor.

What changed since this question was written

2025: a bi-steric mTORC1-selective inhibitor reached humans. In a phase 1 trial of RMC-5552 (Schram, Clin Cancer Res 2025, PMID 41056387, n=57) treatment-related hyperglycaemia occurred in 4% and was not dose-limiting — but mucositis occurred in 49%, so the dose-limiting toxicity moved rather than disappeared. The mechanistic premise also firmed up: bi-sterics reactivate 4E-BP1, which rapalogs cannot, while sparing mTORC2 (Mahauad-Fernandez, Cell Chem Biol 2025, PMID 40803322). No lifespan data exist for any bi-steric in any species.

What is still open

Two things this question had merged. First, does a bi-steric extend lifespan in genetically heterogeneous mice? Untested, and not in any ITP cohort. Second, is rapamycin's glucose intolerance costing anything at all? Lamming 2012 already reported lifespan extension as separable from glucose homeostasis (in female mTOR/mLST8 double-heterozygous mice), and the highest ITP rapamycin dose produces both the largest lifespan gain and glucose intolerance — so the penalty this question proposes to remove may be a biomarker rather than a cost. A further complication: in male mice, lifespan extension by acarbose and 17-alpha-estradiol travels with raised hepatic mTORC2 signalling (Garratt, Aging Cell 2017, PMID 28834262), so mTORC2 tone is not purely a side-effect channel.

The hypothesis

Educated guess: a drug (or dosing schedule) that blocks mTORC1 while leaving mTORC2 alone should give the longevity benefit of rapamycin without the blood-sugar downside.

Technical framing: An intervention that suppresses the mTORC1/4E-BP1 arm while sparing mTORC2 -- now achievable with bi-steric mTORC1-selective inhibitors (RMC-6272/RMC-5552) in addition to intermittent/low-dose rapamycin -- yields the lifespan benefit without glucose intolerance.

How it could be tested

Two experiments, not one. (a) Bi-steric (RMC-6272 class) in an ITP-style lifespan protocol at a dose achieving measurable 4E-BP1 dephosphorylation — the actually untested claim. (b) To test whether the metabolic penalty is a cost: normalise glucose tolerance on top of 42 ppm rapamycin, with acarbose or an SGLT2 inhibitor, and ask whether lifespan moves. Note that bi-sterics (deeper, continuous suppression) and intermittent rapamycin (shallower, pulsed) are opposite manipulations and predict opposite things for muscle and immunity; they should not be pooled as one strategy.

Related studies

Year	Evidence	Study
2012	A	Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity LAM2012 In mice, chronic rapamycin also disrupts mTORC2, causing insulin resistance; reduced mTORC1 signalling alone (female mTOR/mLST8 double-heterozygous mice) extended lifespan without impairing glucose homeostasis.
2015	A	Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system ARR2015 Intermittent rapamycin regimens (weekly, or every 5 days) largely spared glucose tolerance, pyruvate tolerance, fasting glucose and insulin, beta-cell function and the immune system, while still inhibiting mTORC1 -- unlike daily dosing, which impaired all of them. IMPORTANT SCOPE: this study measured side effects only. It did NOT measure lifespan or any other benefit endpoint, so it shows the harm can be reduced, not that the benefit is retained. For evidence that a non-continuous schedule preserves a survival benefit, see ARR2016 (the same every-5-days regimen, started at 20 months, extended female lifespan) and BIT2016.
2014	A	Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction MIL2014 Rapamycin's lifespan extension in mice is dose-dependent and greater in females.
2016	R	The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging KEN2016 A Cell Metabolism review framing mTOR as the 'grand conductor' that coordinates whole-body metabolism, tissue by tissue. Especially valuable for its clear-eyed section on WHY rapamycin causes metabolic side effects (the mTORC2 problem) - which is the main barrier to using it against aging. Pairs perfectly with Lamming's own 2012 mechanism paper.
2009	M	An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 THO2009 Dropped a bombshell: rapamycin does NOT fully block mTORC1. Using Torin1 (which jams the active site directly), the authors showed rapamycin leaves important mTORC1 jobs running - notably 4E-BP1 phosphorylation and autophagy suppression. This reframed a decade of rapamycin experiments and launched the search for complete inhibitors.
2025	H	Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results MOE2025 First completed long-term RCT of rapamycin for healthy human aging (NCT04488601, 48 weeks, n=114). Primary endpoint (visceral fat by DXA) showed NO significant change (p=0.942) - a null result on the pre-registered primary endpoint. Secondary endpoints were more promising: women on the 10mg/week dose had significant improvements in lean tissue mass and self-reported pain. A textbook example of why the pre-registered primary endpoint, not the most exciting secondary finding, is what should drive the headline conclusion.
	RT	Everolimus Aging Study (EVERLAST): Clinical Evaluation of mTORC1 Inhibition for Geroprotection NCT05835999 Currently active phase 2 trial (NCT05835999) directly testing this Atlas's open dosing hypothesis: whether daily low-dose (0.5mg) versus weekly (5mg) everolimus can improve aging biomarkers and insulin resistance in humans without the metabolic penalty seen with continuous higher-dose rapalog use. No results yet - status ACTIVE_NOT_RECRUITING.
2023	A	A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer MEN2023 RMC-6272, a bi-steric molecule with >25-fold selectivity for mTORC1 over mTORC2, completely suppresses mTORC1 (hitting the rapamycin-resistant substrate 4E-BP1) and overcomes hormone- and CDK4/6-inhibitor resistance in breast cancer cell lines and PDX -- the preclinical basis for the RMC-5552 selective-inhibitor clinical program.
2025	H	The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial SCH2025 First-in-human, open-label dose-escalation trial (n=57, advanced solid tumors, no comparator arm) of a bi-steric mTORC1-selective inhibitor. Treatment-related hyperglycemia was low (4%) and not dose-limiting, alongside a 64% disease control rate. Because the trial was uncontrolled and made no head-to-head comparison against rapamycin or an ATP-site inhibitor, this is encouraging early clinical evidence consistent with the hypothesis that sparing mTORC2 reduces metabolic toxicity -- it does not establish mTORC2 sparing as the cause.
2026	A	Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance. MARCHANT2026 Constitutive mTORC1 activation in mouse skeletal muscle (via GATOR1 complex KO) increases inflammatory markers but is not sufficient to impair glucose tolerance, indicating that additional metabolic inputs beyond muscle mTORC1 hyperactivation are required to drive glucose intolerance.
2026	A	Lsp2 links mTORC1 to TOP mRNA translation and lifespan in Drosophila WAN2026 Identifies Lsp2, a Drosophila fat-body storage protein, as an amino-acid-induced feedback activator of mTORC1 that specifically boosts translation of TOP-motif mRNAs (mostly ribosomal proteins) via 4E-BP — a rapamycin-resistant arm of mTORC1 output. Genetic loss of Lsp2 reduces TOP mRNA translation and robustly extends lifespan without cost to reproduction, revealing a rapamycin-independent route from mTORC1 activity to organismal longevity.

Revision history

ShowHide

2026-07-09: Bi-steric inhibitor evidence added (revised 2026-07-29).
2026-08-30: The opening sentence previously read 'Longevity comes from mTORC1 but chronic rapamycin's harm comes from mTORC2 disruption', and the ARR2015 clause read 'inhibited mTORC1 only'. Both were more certain than the experiments support, which is a preferential separation.
2026-09-29: The Lamming 2012 result is now qualified as female mice.
2026-10-03: MARCHANT2026 added - shows in mice that constitutive skeletal-muscle mTORC1 activation raises inflammatory markers but is not sufficient to impair glucose tolerance, weakening the assumed mTORC1-to-glucose-intolerance link at the centre of this question (mouse, muscle-specific genetic model).
2026-10-03: WAN2026 added - shows in Drosophila that lowering the rapamycin-resistant 4E-BP/TOP-translation arm of mTORC1 output extends lifespan without a reproductive cost, supporting the arm-selective premise of this question while saying nothing about mTORC2 sparing or glucose tolerance (fly genetics).
2026-10-03: title rewritten as a question to match Still_Open (was: "mTORC1-selective (mTORC2-sparing) dosing captures longevity without insulin resistance"). URL locked to the old slug via URL_Slug.

← All open questions · Frontier questions

Was this page useful?